ampicillin + amikacin + cefoxitin

This is a combination of three antibiotics—ampicillin, amikacin, and cefoxitin—used together for the treatment of severe or mixed bacterial infections. Each component has a distinct mechanism of action:

• Ampicillin is a beta-lactam antibiotic (penicillin class) that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis.
• Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing misreading of mRNA in susceptible bacteria.
• Cefoxitin is a second-generation cephamycin (cephalosporin) antibiotic that also inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. It has broad-spectrum activity against both Gram-positive and Gram-negative bacteria.

This combination may be used empirically for serious hospital-acquired infections or polymicrobial infections where broad coverage—including resistant Gram-negative organisms and anaerobes—is required. The use of multiple agents can provide synergistic effects but also increases the risk for toxicity (notably nephrotoxicity with aminoglycosides like amikacin). No unique brand name exists for this specific triple combination; it would be prepared as needed in clinical settings.